Chemical Structure (Gabapentin 01)
Chemical structure of gabapentin showing a cyclohexane ring with amino and acetic acid functional groups attached.*
Gabapentin Capsule
Product Images NDC 71205-930
8 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-930). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Gabapentin 02)
A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin scores decreasing over time compared to relatively stable placebo scores.*
Figure 2 (Gabapentin 03)
A line graph depicting the mean pain score over 7 weeks during a study of gabapentin. The x-axis shows weeks from baseline through week 7, and the y-axis shows mean pain score from 0 to 10. The graph compares placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day during a 3-week dose titration period followed by a 4-week fixed dose period. Both gabapentin doses show a decrease in mean pain score over time compared to placebo.*
Figure 3 (Gabapentin 04)
A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at various dosages across two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance levels are indicated with asterisks (p < 0.01 and p < 0.001).*
Figure 4 (Gabapentin 05)
A bar chart comparing the percentage difference in daily gabapentin dose (mg) at 600, 900, 1200, and 1800 mg. It displays data from three different studies labeled Study a, Study b, and Study c, with a vertical axis showing difference in percentage from 2% to 22%.*
71205-928-30 (Image 01)
Gabapentin 100 mg capsules label showing the product from Proficient Rx LP. The label specifies the dosage strength as 100 mg per capsule and indicates the package contains 30 capsules. It includes storage instructions and manufacturer information from ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*
71205-930-30 (Image 02)
Gabapentin 400 mg capsules label from Proficient Rx LP. The label indicates a package size of 30 capsules, each containing 400 mg of gabapentin. Capsules are described as size "0" hard gelatin with an opaque orange cap and body, imprinted with SG on the cap and 181 on the body in black ink. Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*
71205-929-30 (Image 03)
Label for Gabapentin 300 mg capsules, a human prescription drug by Proficient Rx LP. The label states the package contains 30 capsules, each with 300 mg gabapentin, USP, in size "1" hard gelatin capsules with yellow opaque caps and bodies, imprinted with "SG" on the cap and "180" on the body in black ink. Manufactured by ScieGen Pharmaceuticals, Inc.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
